Zhengye Biotech is testing the IPO market with a deal where the headline price is just four dollars.
This is Public Co's. Today, we're looking at what Zhengye Biotech's filing tells us about investor appetite, valuation, and the nuts and bolts of a very small public-market debut.
Tiny IPO. Big signal.
Exactly. So let's start where this starts: the filing.
From the SEC:
This is an initial public offering on a firm commitment basis of our ordinary shares, par value $0.000025 per share (“Ordinary Shares”). Prior to this offering, there has been no public market for our Ordinary Shares. The initial public offering price is $4.00 per Ordinary Share.
Yep, classic IPO fine print: new listing, no prior public market, and right up front, a warning that investors could lose everything. You don't skip that part. That's the risk label on the box.
You'll find links to all of today's stories in the show notes, so if something caught your ear, you can go straight to the source.
That's Public Co's for today. Thanks for listening, and enjoy the rest of your Sunday. This is a Lantern Podcast.